<生产厂家价格>

L-鸟氨酸L-天门冬氨酸

L-鸟氨酸L-天门冬氨酸用途

L-Ornithine L-aspartate 由两种天然的非必需 L-氨基酸组成：鸟氨酸和天冬氨酸。L-Ornithine L-aspartate 可降低血氨浓度并消除与肝硬化相关的肝性脑病的症状。

L-鸟氨酸L-天门冬氨酸名称

[ CAS 号 ]:
3230-94-2

[ 中文名 ]:
L-鸟氨酸 L-天门冬氨酸盐

[ 英文名 ]:
L-Ornithine L-aspartate salt

[中文别名 ]:

[英文别名 ]:

L-Ornithine L-Aspartate Salt
L-Ornithine L-Aspartate
L-Ornithine-L-Aspartate
L-Aspartic acid - L-ornithine (1:1)
EINECS 221-772-7
L-OrnithineL-aspartatesalt
(S)-2,5-Diaminopentanoic acid L-aspartate salt
Hepa-Merz (TN)
L-Ornithin-L-aspartat
L-Aspartic acid, compd. with L-ornithine (1:1)

L-鸟氨酸L-天门冬氨酸生物活性

[ 描述 ]:

L-Ornithine L-aspartate 由两种天然的非必需 L-氨基酸组成：鸟氨酸和天冬氨酸。L-Ornithine L-aspartate 可降低血氨浓度并消除与肝硬化相关的肝性脑病的症状。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 代谢疾病

[参考文献]

[1]. Sikorska H, et al. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency]. Pol Merkur Lekarski. 2010 Jun;28(168):490-5.

L-鸟氨酸L-天门冬氨酸物理化学性质

[ 沸点 ]:
308.7ºC at 760 mmHg

[ 分子式 ]:
C₉H₁₉N₃O₆

[ 分子量 ]:
265.264

[ 闪点 ]:
140.5ºC

[ 精确质量 ]:
265.127380

[ PSA ]:
189.96000

[ LogP ]:
0.11110

[ 外观性状 ]:
白色粉末

[ 储存条件 ]:
2-8°C

L-鸟氨酸L-天门冬氨酸MSDS

详细MSDS(安全技术说明书)

L-鸟氨酸L-天门冬氨酸毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CI9463000

CAS REGISTRY NUMBER :: 3230-94-2

LAST UPDATED :: 199701

DATA ITEMS CITED :: 5

MOLECULAR FORMULA :: C5-H12-N2-O2.C4-H7-N-O4

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85IPAE "Modern Pharmaceuticals of Japan, III," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1968 Volume(issue)/page/year: -,91,1968

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,164,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,164,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85IPAE "Modern Pharmaceuticals of Japan, III," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1968 Volume(issue)/page/year: -,91,1968

L-鸟氨酸L-天门冬氨酸安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S26-S37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
CI9463000

[ 海关编码 ]:
2922499990

L-鸟氨酸L-天门冬氨酸海关

[ 海关编码 ]: 2922499990

[ 中文概述 ]:
2922499990 其他氨基酸及其酯及它们的盐（含有一种以上含氧基的除外）. 增值税率:17.0% 退税率:9.0% 监管条件:AB(入境货物通关单,出境货物通关单) 最惠国关税:6.5% 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装

[ 监管条件 ]: A.入境货物通关单 B.出境货物通关单

[ 检验检疫 ]: P.进境动植物、动植物产品检疫 Q.出境动植物、动植物产品检疫 R.进口食品卫生监督检验 S.出口食品卫生监督检验 M.进口商品检验 N.出口商品检验

[ Summary ]:
HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0%

L-鸟氨酸L-天门冬氨酸文献

Modulation of neural activation following treatment of hepatic encephalopathy.

Neurology 80(11) , 1041-7, (2013)

To measure changes in psychometric state, neural activation, brain volume (BV), and cerebral metabolite concentrations during treatment of minimal hepatic encephalopathy.As proof of principle, 22 pati...

L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.

J. Gastroenterol. Hepatol. 24(1) , 9-14, (2009)

Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently ...

A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.

Liver Int. 30(4) , 574-82, (2010)

Hepatic encephalopathy (HE) is a complication of liver disease. Several treatments have been introduced but only L-ornithine-L-aspartate (LOLA) shows proven efficacy. This double-blind, randomized, pl...

更多文献